Seoul, Korea, South, June 22, 2017 - The advent of artificial intelligence (AI) has global pharmaceutical companies and startups in a race to develop new products and services in all sectors. The field of healthcare is no exception with the U.S. leading the way in AI startups. Many startups partner with bigger companies or become part of the latter. The National Information Society Agency released a report Tuesday on promising AI startups in Korea, including six in the field of healthcare – Neofect, Vuno, Tomocube, Lunit, Standigm, and Bitfinder.
News Standigm announces partnership with Ajou University College of Pharmacy to discover a new small molecule drug for Parkinson’s disease.
News Standigm and Ajou university medical center sign MOU for an AI-driven clinical drug development
Press CrystalGenomics and Standigm, Agree to Collaborate on Utilizing Artificial Intelligence and Structure-Based Drug Design Technologies in Drug R&D
Seoul, Korea, South, June 01, 2017 –(PR.com)– CrystalGenomics, Inc. (KOSDAQ: 083790) and Standigm, Inc., today announced the collaborative partnership to apply Artificial Intelligence (AI) to the research and development of novel drugs.
News Standigm and CrystalGenomics announce partnership to discover novel therapeutics in cancer, rheumatoid arthritis and liver related diseases.
Standigm, Inc. and CrystalGenomics, Inc. today agree collaborative partnership with the objective to discover and develop first-in-class drugs in the multiple therapeutic areas including cancer, rheumatoid arthritis and liver related diseases.